Destabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeutics by Woodcock, Joanna M. et al.
City University of New York (CUNY) 
CUNY Academic Works 
Publications and Research Queens College 
2015 
Destabilisation of dimeric 14-3-3 proteins as a novel approach to 
anti-cancer therapeutics 
Joanna M. Woodcock 
University of South Australia 
Carl Coolen 
University of South Australia 
Katy L. Goodwin 
University of South Australia 
Dong Jae Baek 
CUNY Queens College 
Robert Bittman 
CUNY Queens College 
See next page for additional authors 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/qc_pubs/20 
Discover additional works at: https://academicworks.cuny.edu 
This work is made publicly available by the City University of New York (CUNY). 
Contact: AcademicWorks@cuny.edu 
Authors 
Joanna M. Woodcock, Carl Coolen, Katy L. Goodwin, Dong Jae Baek, Robert Bittman, Michael S. Samuel, 
Stuart M. Pitson, and Angel F. Lopez 
This article is available at CUNY Academic Works: https://academicworks.cuny.edu/qc_pubs/20 
Oncotarget14522www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 16
Destabilisation of dimeric 14-3-3 proteins as a novel approach 
to anti-cancer therapeutics
Joanna M. Woodcock1, Carl Coolen1, Katy L. Goodwin1, Dong Jae Baek2, Robert 
Bittman2,**, Michael S. Samuel1,3, Stuart M. Pitson1,3,* and Angel F. Lopez1,3,*
1 Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia
2 Department of Chemistry and Biochemistry, Queens College of the City University of New York, Flushing, NY, USA
3 School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, SA, Australia
* These authors have contributed Equally to this work
** Deceased
Correspondence to: Joanna M. Woodcock, email: Joanna.Woodcock@health.sa.gov.au
Keywords: biochemistry, signal transduction, sphingosine, apoptosis, small molecules
Received: March 24, 2015 Accepted: April 11, 2015 Published: May 04, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
14-3-3 proteins play a pivotal role in controlling cell proliferation and survival, 
two commonly dysregulated hallmarks of cancers. 14-3-3 protein expression is 
enhanced in many human cancers and correlates with more aggressive tumors 
and poor prognosis, suggesting a role for 14-3-3 proteins in tumorigenesis and/
or progression. We showed previously that the dimeric state of 14-3-3 proteins 
is regulated by the lipid sphingosine, a physiological inducer of apoptosis. As the 
functions of 14-3-3 proteins are dependent on their dimeric state, this sphingosine-
mediated 14-3-3 regulation provides a possible means to target dimeric 14-3-3 for 
therapeutic effect. However, sphingosine mimics are needed that are not susceptible 
to sphingolipid metabolism. We show here the identification and optimization of 
sphingosine mimetics that render dimeric 14-3-3 susceptible to phosphorylation at 
a site buried in the dimer interface and induce mitochondrial-mediated apoptosis. 
Two such compounds, RB-011 and RB-012, disrupt 14-3-3 dimers at low micromolar 
concentrations and induce rapid down-regulation of Raf-MAPK and PI3K-Akt signaling 
in Jurkat cells. Importantly, both RB-011 and RB-012 induce apoptosis of human 
A549 lung cancer cells and RB-012, through disruption of MAPK signaling, reduces 
xenograft growth in mice. Thus, these compounds provide proof-of-principle for this 
novel 14-3-3-targeting approach for anti-cancer drug discovery.
INTRODUCTION
The family of 14-3-3 proteins plays a pivotal role 
in integrating cellular survival signaling and thereby are 
key players in determining the cell fate [1, 2]. Through 
their role in binding multiple phospho-client proteins 
within the cell, 14-3-3 proteins regulate many important 
signaling events. In particular, 14-3-3 proteins maintain 
the proliferative capacity of the cell by supporting the 
efficient activation of the Raf-MAPK signaling cascade 
and also support cell survival through the PI3K-AKT 
signaling cascade [1, 2], key requirements of cancer cells 
[3]. 
Enhanced expression of 14-3-3 proteins has been 
detected in many human cancers including lung [4], 
head and neck [5], breast [6] and ovarian cancer [7] and 
correlates with more aggressive tumors and poor prognosis 
[8]. Over-expression of 14-3-3 isoforms has been shown to 
contribute to neoplastic transformation by stimulating Raf-
MAPK and PI3K signaling [9]. Down-regulation of 14-3-
3ζ in head and neck cancer cells [10] and also lung cancer 
cells [11] renders cells more sensitive to chemotherapy, 
supporting the notion that cancer cells utilize mechanisms 
that are 14-3-3 dependent. These experimental and clinical 
observations suggest that 14-3-3 proteins represent an 
addiction for many cancers and consequently are an 
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attractive target for anti-cancer therapy [8, 12]. 
In search of 14-3-3 inhibitors, several studies have 
identified small molecules that function as mimics of 14-
3-3 binding partners, blocking the interaction of 14-3-
3 proteins with phospho-clients such as c-Abl [13] and 
Raf-1 [14], and thus behaving as competitive antagonists. 
These small molecule inhibitors of 14-3-3 proteins exhibit 
anti-cancer activity in cell-based assays but are limited 
by their specificity, ability to penetrate cells and also the 
need for high concentrations to effectively compete with 
abundant endogenous 14-3-3-binding proteins. 
We have taken a novel approach to developing 
14-3-3-targeting molecules by exploiting the requirement 
of 14-3-3 proteins to function as dimers [15]. 14-3-3 
proteins are intrinsically dimeric in nature, a characteristic 
which is obligatory for many of their biological functions 
[16]. We showed previously that the dimeric status of 14-
3-3 proteins is subject to regulation, with the critical step 
being phosphorylation of Ser58 (numbering relates to the 
ζ isoform), a site otherwise buried in the dimer interface 
[17]. The Ser58 dimer interface phosphorylation site is 
conserved in five of the seven mammalian isoforms and is 
recognized by several kinases [18-20] but, importantly, we 
showed it only becomes accessible after the endogenous 
lipid sphingosine binds to the 14-3-3 protein [15]. Once 
Ser58 is phosphorylated, the dimeric structure of the 14-
3-3 protein is disrupted and its function is inhibited [17]. 
Thus, through this mechanism, sphingosine serves as a key 
regulator of dimeric 14-3-3 protein function and induces 
apoptosis [15]. 
Similarly, we found that the synthetic sphingosine 
analogue, FTY720, also renders 14-3-3 phosphorylatable 
[15]. FTY720, also known as Fingolimod and GilenyaTM, 
is in clinical use to induce immune suppression in the 
treatment of multiple sclerosis, but has reported anti-cancer 
characteristics in many experimental systems [21]. As an 
immune suppressant, FTY720 is a pro-drug which relies 
on conversion to a phosphorylated form for its effects, 
predominantly as a sphingosine-1-phosphate receptor 
antagonist [21]. The anti-cancer effects of FTY720 
however are associated with the unphosphorylated pro-
drug form [21] and we have shown that these are mediated 
in part by its effect on 14-3-3 proteins [15]. Owing to its 
immunosuppressant properties, FTY720 is not a suitable 
anti-cancer therapy but understanding the molecular basis 
of its anti-cancer action has provided us with a rationale 
to identify more sphingosine-like compounds that target 
14-3-3 specifically. 
We have now surveyed other sphingosine-like 
molecules and demonstrate that N-alkylated trimethyl 
ammonium (TMA) molecules act as sphingo-mimics 
to disrupt 14-3-3 dimers and induce apoptosis in Jurkat 
cells. Because these compounds are unsuitable drug 
candidates, we have combined the chemical nature of the 
TMAs with the FTY720 backbone to generate a novel 
chemical series that exhibit apoptotic characteristics 
through a 14-3-3-mediated mechanism in vitro. 
Furthermore, we have demonstrated that the most potent 
of this chemical series induce mitochondrial-mediated 
apoptosis at low micromolar concentrations in vitro 
and rapidly elicit a signaling cascade that corresponds 
kinetically to the disruption of dimeric 14-3-3 functions. 
In a mouse xenograft model of human non-small cell 
lung cancer where 14-3-3 is over-expressed, RB-012, 
our most active compound significantly reduced tumor 
growth without adverse effects on the animals. Our data 
show that RB-012 is soluble, readily taken up by cells, 
effective at low concentration and unlike other previously 
reported 14-3-3-directed small molecules, acts via a 
non-competitive mechanism. This compound and the 
mechanism that underlies its activity provide proof-of-
principle for our approach to developing a new class of 
14-3-3-targeting small molecule therapeutics for cancer 
treatment.
RESULTS
Trimethylammonium compounds render the 14-3-
3 dimer interface accessible to kinases and induce 
mitochondrial apoptosis
We previously established that non-acylated 
sphingolipids with a net positive charge are capable of 
rendering 14-3-3 phosphorylatable [15]. To identify 
new compounds that are capable of rendering 14-3-3 
phosphorylatable but are not susceptible to sphingolipid 
metabolism, we assessed non-sphingoid cationic lipids 
such as quaternary ammonium compounds for effects on 
14-3-3 phosphorylatability. In our in vitro system using 
recombinant 14-3-3ζ as substrate and PKA catalytic 
subunit as the phosphorylating enzyme, we found that 
trimethylammonium (TMA) molecules with an alkyl chain 
of 14 carbons or longer rendered 14-3-3 phosphorylatable, 
whereas molecules with a shorter alkyl chain were 
ineffective (Figure 1A & 1B).
 We next tested whether the N-alkyl TMA 
series could induce cell death of Jurkat cells. Cell 
death was assessed using flow cytometry after 20 h 
of treatment by analysis of cell viability together with 
tetramethylrhodamine ethyl ester (TMRE) staining to 
monitor mitochondrial permeability transition (∆ΨM), 
an event commonly associated with programmed cell 
death (Figure 1C). The longer chain N-alkyl TMA 
molecules induced mitochondrial permeability transition 
at 5µM, consistent with their ability to render 14-3-3 
phosphorylatable. This suggests that like sphingosine, 
these longer chain TMA molecules can regulate dimeric 
14-3-3 proteins to disrupt their functions in cells. 
To elucidate the mechanism of the TMA compound’s 
effect on 14-3-3 protein, we carried out dose-response 
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studies with C16-TMA, (cetyltrimethylammonium 
bromide, denoted as CTAB) in 14-3-3 phosphorylation 
reactions. We observed a dose-dependent increase in 14-
3-3 Ser58 phosphorylation with increasing concentration 
of CTAB (Figure 2A) and using recombinant S58A 14-
3-3ζ protein, confirmed that Ser58 was the only site 
phosphorylated by PKA (Figure 2A), consistent with our 
previous studies with sphingosine, and FTY720 [15]. 
Additionally, we observed no effect of CTAB on PKA 
catalytic subunit activity (as determined using kemptide 
phosphorylation) over the same concentration range (data 
not shown), reinforcing that CTAB has a direct effect on 
the 14-3-3 protein, not on enzyme activity.
Long chain N-alkylated TMA molecules are 
amphiphilic with a cationic head group and a long alkyl 
chain and can therefore behave as cationic detergents. The 
reported critical micelle concentration for CTAB in water 
is 1 mM but in 20 mM Tris-Cl pH 7.0, 10 mM NaCl the 
CMC decreases to ~ 0.15 mM [25]. We therefore assessed 
CTAB’s effect on 14-3-3 phosphorylation more closely 
to determine whether non-specific denaturation of 14-3-3 
was contributing to the phosphorylatability of 14-3-3 by 
PKA. In extended dose-response studies, CTAB induced 
14-3-3 phosphorylation at low micromolar concentrations, 
plateauing at 25 µM, but above 75 µM a further increase 
in 14-3-3 phosphorylation was observed (Figure 2B). This 
implies that at low micromolar concentrations, CTAB 
binds discrete sites in 14-3-3, thereby conformationally 
Figure 1: A. Structures of the trimethylammonium (TMA) compounds assessed for 14-3-3 modulating activity. B. Phosphorylation of 
14-3-3 by PKA in vitro in presence or absence of TMA compounds at the concentrations shown. The upper panel is [32P]-phospho-labeled 
14-3-3ζ and the lower panel is Coomassie stained 14-3-3 protein. C. Effect of TMA compounds on Jurkat cell after 20 h treatment at the 
concentrations shown. Cell viability is shown in open bars and TMRE negative staining cells are shown in black bars. The error bars show 
the range of duplicate determinations: and the results are representative of multiple experiments. 
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altering the dimer interface to reveal the Ser58 
phosphorylation site accessible to PKA, whereas at 
higher concentrations of CTAB, approaching CMC 
values, a more cooperative effect is seen, consistent with 
generalized protein denaturation. Consistent with this, 
PKA catalytic subunit activity was significantly inhibited 
at higher CTAB concentrations (Figure 2B, kemptide 
phosphorylation was reduced by 90% in the presence of 
100 µM CTAB compared with vehicle alone) presumably 
due to the denaturation of the enzyme. Similar effects 
have been observed for C14-TMA binding to bovine serum 
albumin, with saturable binding to specific high affinity 
Figure 2: A. In vitro phosphorylation of 14-3-3ζ (Wt and S58A) by PKA in the presence of increasing concentrations of CTAB (C16-
TMA). B. Quantitation of 14-3-3ζ phosphorylation (solid symbols and solid line) and PKA activity (open symbols and dashed line) with 
increasing CTAB concentration. C. Effect of 5µM CTAB on cell viability (FS vs. SS plots inset) and caspase-3 activation (histograms) in 
parental Jurkat cells (left panel) and Jurkat cells over-expressing Bcl-2 (right panel) after 20 h.
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Figure 3: A. Structures of the TMA-FTY720 hybrid RB compounds and their effect on in vitro 14-3-3ζ phosphorylation by PKA at the 
concentrations as shown. The upper panel is [32P]-phospho-labeled 14-3-3ζ ([32P]) and the lower panel Coomassie-stained 14-3-3ζ protein 
(C). B. Effect of 5 µM RB molecules on viability (open bars) and caspase-3 activation (black) of Jurkat cells after 5 h treatment. C. Effect 
of 5 µM RB compounds on viability (open bars) and Annexin V staining (hashed bars) of Jurkat cells after 24 h treatment. The error bars 
show the range of duplicate determinations and the results are representative of multiple experiments. 
Oncotarget14527www.impactjournals.com/oncotarget
sites at low C14-TMA concentrations and cooperative non-
specific binding at high concentrations [26].
To test whether the mitochondrial permeability 
transition induced by CTAB is associated with apoptosis, 
akin to the effect of sphingosine and FTY720 [15], we 
examined caspase-3 activation, a characteristic marker 
of apoptosis. As shown in Figure 2C, CTAB does induce 
caspase-3 activation in Jurkat cells and, as with FTY720 
[27], Jurkat cells over-expressing Bcl-2 were protected 
from CTAB-induced cell death, confirming that the 
CTAB-induced apoptosis is mediated by the mitochondria. 
Thus, these data show that at concentrations well below 
the CMC, N-alkyl TMA molecules are able to bind to 14-
3-3 proteins in cells, leading to disruption of 14-3-3 dimers 
and subsequent induction of mitochondrial apoptosis.
Development of the novel RB sphingomimetics 
and their modulation of 14-3-3 dimerisation and 
induction of mitochondrial apoptosis
Our results with CTAB suggest that at 
concentrations below its CMC, this molecule can bind to 
discrete sites in 14-3-3 proteins, causing conformational 
Figure 4: A. Dose response of caspase-3 activation (detected by flow cytometry using NucViewTM) in Jurkat cells after 5 h treatment 
with RB-011 (pink squares), RB-012 (blue triangles) or vehicle (Veh). The error bars show the range of duplicate determinations. B. 
Immunoblotting of Jurkat lysates after 4 h treatment of cells with either vehicle or 7.5 µM RB-011 or RB-012. C. Effect of RB-011 
(pink) and RB-012 (blue) on cell viability (shown by line graph) and caspase-3 activation (histograms) in parental Jurkat cells (solid lines 
and color) and Jurkat cells over-expressing Bcl-2 (dashed lines and hashed color) after 20 h treatment. The error bars show the range of 
duplicate determinations and the results are representative of several experiments.
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changes at the dimer interface and thereby allowing 
kinases access to the Ser58 phosphorylation site. CTAB 
however, is not an ideal anti-cancer candidate owing to 
its strong detergent properties and known toxic effects in 
mice. Data generated by the Developmental Therapeutics 
Program at the National Cancer Institute indicate that 
CTAB is toxic in mice when dosed above 10 mg/kg over 
a five day treatment, (mined from < http://dtp.nci.nih.
gov/dtpstandard/dwindex/index.jsp>). The clinical drug 
FTY720 has previously been used in mice at 10 mg/kg 
with no reported adverse effects, although its clinical 
application is as an immunosuppressant, an activity 
associated with the phosphorylated form of FTY720 
[21]. In order to generate more 14-3-3-selective agents 
we sought to combine the charged quaternary ammonium 
group of the TMA molecules with the clinically approved 
FTY720 alkyl chain, and thereby generated a panel of 
new quaternary amine derivatives of FTY720, denoted 
here as RB-011, -012, -066, -067 and -068 (Figure 3A). 
Unlike sphingosine and FTY720, these analogues lack 
hydroxyl sites for phosphorylation by sphingosine kinases 
and therefore cannot be converted to immunosuppressive 
phospho-species.
Initially we tested the five RB compounds in our 
in vitro 14-3-3 phosphorylation assay. In dose response 
studies we found RB-011 and RB-012 were the most 
effective at rendering 14-3-3 phosphorylatable by PKA, 
whereas the other compounds were much less effective 
(Figure 3A). We then assessed the ability of the RB 
compounds to induce apoptosis of Jurkat cells compared 
with FTY720, CTAB and RB-015 [22], a hydroxylated 
version of RB-012 (in which the hydroxyl group is at the 
4 position of the piperidinium ring, ref. 22). At 5 µM, 
RB-011 and -012 were readily able to activate apoptosis 
as determined by caspase-3 activation within 5 h (Figure 
3B), and Annexin V presentation and loss of viability at 
Figure 5: A. Immunoblotting analysis of signaling molecules (as shown) over time induced by 7.5 µM RB-012 treatment of Jurkat cells. 
B. Immunoblotting analysis of apoptotic signals (as shown) over time induced by 7.5 µM RB-012 treatment of Jurkat cells.
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24 h (Figure 3C), consistent with their ability to elicit 14-
3-3 phosphorylation at low concentration. Importantly 
RB-011 and -012 were more potent than either CTAB 
or FTY720. None of the other RB compounds were as 
effective at inducing Jurkat cell apoptosis consistent with 
their effect on 14-3-3 phosphorylation and indicating that 
ring substitution is not tolerated for these activities (Figure 
3).
The potency and apoptotic effects of RB-011 and 
-012 on cells were examined more closely. We determined 
the ED50 for apoptosis induction in Jurkat cells by 
assessing the activation of caspase-3 at 5 h, before any 
significant loss of cell viability (Figure 3B). RB-012 was 
slightly more potent than RB-011 at initiating apoptosis, 
with an ED50 of 2 µM compared with 3 µM for RB-011 
(Figure 4A). Biochemical characterization of RB-treated 
Jurkat cells revealed that after 4 h of treatment PARP 
cleavage had occurred, consistent with the commitment 
to apoptosis (Figure 4B, upper panels). Using phospho-
specific antibodies, we detected active stress-activated 
protein kinases, p38 and JNK, after 4 h of treatment with 
RB-011 or -012 (Figure 4B, second and third panel). 
Immunoblotting of 14-3-3 revealed a slightly lower 
molecular weight form of 14-3-3 after 4 h of RB-011 
or -012 treatment (Figure 4B, bottom panel) probably 
associated with caspase cleavage as 14-3-3 proteins have 
previously been shown to be susceptible [28]. 
These analyses indicate that the activation of 
apoptosis in response to the RB compounds is rapid, 
and detectable by 4 h of treatment. Additionally and 
Figure 6: A. Viability of NSCLC cell line A549 is inhibited by RB-011 and RB-012 as determined by MTS assay after 48 h treatment. 
Error bars represent standard error of triplicate measurements. B. RB-011 and RB-012 induce caspase-3 activation at 48 h in A549 cells. 
The error bars show the range of duplicate determinations: and the results are representative of several experiments. C. Effect of RB-011 
and -012 on A549 colony growth in soft agar. Results are expressed relative to colony numbers in untreated controls. D. Immunoblotting 
analysis of phospho-ERK over time induced by 25 µM RB-012 treatment of A549 cells. E. Growth of A549 xenograft in BALB/c nude mice 
is retarded by administration of RB-012. RB-012, saline or FTY720 was administered daily to mice bearing A549 tumors by intraperitoneal 
injection using the dosing regime shown. All experimental data are shown as the mean ± SEM. ** indicates P < 0.05. F. RB-012 induces 
down-regulation of MAPK signaling in A549 xenografts. Tumors were excised at the end of the study and analyzed by immunofluorescence 
for phospho-ERK. Area coverage analysis is represented by a box and whisker plot. Statistical significance was assessed using the Mann-
Whitney test and Dunnet’s post hoc test, ** indicates P < 0.05 for N = 7 samples with multiple fields analyzed. Representative images of 
phospho-ERK immunofluorescence are shown below, scale bar – 100 µm.
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importantly, over-expression of Bcl-2 completely 
protected the Jurkat cells from the RB compounds (Figure 
4C) as determined by analysis of viability and caspase 
activation after 20 h of treatment, confirming that the 
compounds initiate signaling upstream of mitochondrial-
mediated apoptosis.
The novel RB sphingomimetics cause rapid 
inhibition of PI3K-AKT and MAPK signaling
To characterize the signaling changes associated 
with RB treatment of Jurkat cells, we carried out time-
course studies using RB-012 and prepared cytosolic 
extracts for immunoblotting. Strikingly, phospho-specific 
antibodies revealed rapid dephosphorylation of both ERK 
and AKT (within 1 h) upon RB-012 treatment (Figure 
5A first and third panels), indicating down-regulation of 
the MAPK and PI3K signaling pathways respectively. 
Activation of SAPKs p38 and JNK was detected but not 
until 2 h post RB-012 treatment (Figure 5A fourth and fifth 
panels), after ERK and AKT inactivation. 
In the same time-course studies, apoptotic markers 
were analyzed by immunoblotting. BID cleavage is 
associated with diverse apoptotic stimuli and has been 
shown to occur after mitochondrial permeability transition 
and apoptotic commitment via a caspase-3 mediated 
process in Jurkat cells [29]. We analyzed BID cleavage 
after RB-12 treatment and found that BID breakdown 
is detected at 3 h of RB-012 treatment (Figure 5B, first 
panel). Immunoblotting for 14-3-3 over the time-course 
revealed that the lower molecular weight form of 14-3-
3 protein is detected at 2 h (Figure 5B, second panel), 
consistent with activation of caspase-3 (Figure 5B, third 
panel). Additionally, PARP cleavage was detectable at 2 h 
(Figure 5B, fourth panel). Thus commitment to apoptosis 
in response to RB-012 occurs within 2-3 h of treatment, 
after the initial effects on MAPK and PI3K signaling. 
RB sphingomimetics inhibit A549 lung cancer cell 
growth in vitro and in vivo
RB-011 and -012 exhibit apoptotic activity on 
Jurkat cells. Their effects are mediated at least in part by 
disruption of functional 14-3-3 dimers and inactivation of 
AKT and MAPK signaling pathways. These characteristics 
are desirable for a new anti-cancer therapy. We therefore 
sought to validate these compounds on human cancer 
cells where 14-3-3 over-expression has been implicated 
in tumor aggression. Of the multiple cancer types where 
14-3-3 over-expression has been detected, non-small cell 
lung cancer (NSCLC) has been identified as a cancer in 
which the degree of 14-3-3ζ over-expression correlates 
strongly with poor patient survival and disease severity 
[4]. We therefore assessed the effect of the RB-011 and 
-012 molecules on the NSCLC line A549 (Figure 6). 
First, we performed survival assays using MTS 
and found that the RB compounds reduced cell viability 
in a dose-dependent manner (Figure 6A). As with the 
Jurkat cells, RB-012 was slightly more potent than RB-
011 with an IC50 of 5.5 µM compared with 7 µM for 
RB-011 (Figure 6A). We assessed the ability of the RB 
compounds to induce A549 cells apoptosis by monitoring 
caspase-3 activation. Both compounds induced caspase-3 
activation with RB-012 showing greater potency at 10 µM 
(Figure 6B). The compounds were then tested for their 
effect on A549 colony formation in soft agar, a measure 
of neoplastic growth. Both compounds reduced colony 
formation in a dose-dependent manner with RB-012 again 
showing slightly greater potency (Figure 6C). 
A549 cells harbor oncogenic K-Ras and 
consequently constitutive MAPK signaling is 
characteristic of this cell line. We analyzed the effect of 
RB-012 on MAPK signaling in the A549 cells in vitro and 
observed a rapid reduction in phospho-ERK in response 
to RB-012 (Figure 6D). Thus given RB-012’s activity in 
vitro, we then studied its effects in vivo. 
To assess any potential toxicity, BALB/c nude mice 
were administered either RB-012 or FTY720, delivered in 
saline (0.9%), daily by i.p. injection at 5mg/kg or 10mg/
kg body weight, doses previously reported for FTY720 
administration [21]. Over a course of 28 days there were 
no adverse effects associated with RB-012 treatment with 
the exception of apparent pain and abdominal cramping 
in the mice immediately after injection which subsided 
within 10-20 min. Similar effects were also observed 
with 5mg/kg/day FTY720 treatment. Importantly 
there was no pathology associated with the abdominal 
cramping suggesting a physiological response and over 
time the mice developed a tolerance to this effect. The 
body weight of RB-012 treated mice was unaltered over 
the course of the toxicity study and histology of tissues 
(liver, lung, kidney, heart and spleen) collected during the 
treatment course was unaffected (supplementary Figure 
2A) indicating that the RB-012 had no major toxic effects. 
Additionally, bone marrow samples from RB-012 treated 
mice exhibited no alterations indicating no changes in 
steady state haemopoiesis (supplementary Figure 2B). In 
the same toxicity study we found that FTY720 dosed at 
10mg/kg body weight was poorly tolerated and caused 
cardiac arrhythmia with one unexplained fatality. Toxicity 
has previously been noted with i.p. injection of FTY720 
at 10mg/kg/day [30] and we were therefore unable to use 
this dose of FTY720 in the subsequent xenograft study. 
To assess the effect of RB-012 on human lung 
cancer growth in vivo, A549 cells were implanted 
subcutaneously on the flanks of BALB/c nude mice and 
tumors were allowed to grow until they had reached a 
volume of 100 mm3. RB-012, FTY720 or saline was then 
administered daily to assess the effect on tumor growth. 
Owing to the physiological abdominal cramping response 
observed in the toxicity study, we were required on ethical 
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grounds to use a dose escalation regime for administering 
both RB-012 and FTY720 to allow the mice to develop 
tolerance. Initially, dosing was limited to 2mg/kg body 
weight for two days and then increased to 5mg/kg daily 
for two weeks which minimized the cramping. Tumor 
volume was monitored twice a week and after two weeks 
of dosing at 5mg/kg body weight, mice administered RB-
012 had tumors that were 20% smaller than mice receiving 
saline (Figure 6E). Interestingly, mice receiving FTY720 
showed no reduction in tumor size (Figure 6E) in contrast 
to a previous report employing A549 xenografts [31] albeit 
in a different mouse strain (Balb/c SCID) and using a 
different route of FTY720 administration (by oral gavage).
As RB-012 was better tolerated than FTY720, the 
dosing of RB-012 treated mice was increased to 10mg/
kg body weight for a further week with no adverse effects 
on the mice. The tumors on the RB-012-treated mice 
continued to grow more slowly than those on saline treated 
mice and at the end of the treatment course were  30% 
smaller than those of saline-treated mice (Figure 6E). Thus 
RB-012 effectively reduced A549 tumor growth whereas 
FTY720 was ineffective in this study.
To provide evidence that the anti-cancer effect of 
RB-012 in the A549 xenograft study involved disruption 
of dimeric 14-3-3, we analyzed the excised tumor tissue 
for MAPK activity. Quantitative immunofluorescence 
analysis showed that tumors treated with RB-012 had 
significantly less phospho-ERK than saline-treated tumors 
(Figure 6F), consistent with the in vitro results on A549 
cells (Figure 6D). Thus RB-012 effectively reduces A549 
xenograft growth by a mechanism involving disruption 
of the oncogenic signaling in these cells, supporting the 
notion that RB-012 reduces tumor growth by disruption 
of dimeric 14-3-3 function.
DISCUSSION
The widespread over-expression of 14-3-3 proteins 
in human tumors has highlighted the significance of 14-3-
3 proteins in cancer development [4-8]. Increased 14-3-3 
expression provides cancer cells with enhanced protection 
against apoptotic mediators making 14-3-3 proteins an 
attractive target for anti-cancer drug development. Several 
groups have identified molecules with the ability to block 
the binding of 14-3-3 proteins to client proteins [13, 14, 
32]. Without exception these molecules compete with 
client proteins for binding in the amphipathic groove [32]. 
We have developed a novel approach that exploits discrete 
sphingolipid binding site(s) on 14-3-3 that when occupied, 
causes dimer disruption and loss of function [15]. 
We have now identified N-alkylated 
trimethylammonium (TMA) molecules as modulators of 
14-3-3 in vitro with a corresponding capacity to induce 
apoptosis of Jurkat cells (Figure 1). From a chemical 
series of trimethylammonium compounds we determined 
that the length of the alkyl chain is an important factor in 
determining the effect on 14-3-3 modulation and Jurkat 
cell apoptosis. Long-chain TMAs have the greatest 
potency both in in vitro 14-3-3 phosphorylation assay 
and inducing Jurkat cell apoptosis (Figure 1). We have 
demonstrated that at low micromolar concentrations 
(below the CMC), CTAB modulates 14-3-3ζ, allowing 
phosphorylation by PKA at Ser58 in the dimer interface, 
in an analogous fashion to sphingosine and its analogues 
[15]. Additionally, the long-chain TMAs induce apoptosis 
in Jurkat cells at concentrations well below CMC via the 
mitochondrial pathway (Figure 2). These data support 
the notion that long-chain TMAs induce apoptosis by 
interfering with dimeric 14-3-3 in the cell. 
CTAB was previously identified in a high-
throughput screen for anti-cancer agents as being able 
to inhibit the growth of a panel of head and neck cancer 
(HNC) cell lines and reduce mitochondrial membrane 
potential (∆ΨM) but the mechanism of action was unknown 
[33]. Consistent with our results, the apoptotic effect of 
CTAB was related to the length of the alkyl group [33]. 
Furthermore, CTAB administration at 5 mg/kg retarded 
the growth of HNC xenografts in vivo [33]. 14-3-3ζ over-
expression has been reported in HNCs and correlates 
with poor patient prognosis [5] and knock-down of 14-3-
3ζ in HNC cell lines by RNAi inhibited cell growth and 
increased apoptosis in response to chemotherapy [10]. Our 
results strongly suggest that the effects of CTAB on HNC 
lines are attributable to 14-3-3 dimer disruption. 
CTAB has also been assessed for anti-cancer 
activity in the National Cancer Institute Developmental 
Therapeutics Program (<www.dtp.nci.nih.gov>) in 
mouse cancer models of lymphocytic leukemia (P388 
and L1210) and melanoma (B16). A modest therapeutic 
effect was seen in the P388 model at low doses, at 3 and 
6 mg/kg body weight per day i.p. 20 % more of the mice 
survived to 30 days of treatment compared with untreated 
controls. At high dose (>10 mg/kg body weight) CTAB 
was toxic (after 5 days treatment, data extracted from DTP 
at NCI) and given its strong surfactant properties is not 
suitable as a drug candidate. However, CTAB’s ability 
to disrupt 14-3-3 dimers, allowing phosphorylation in 
the dimer interface, coincident with its ability to induce 
mitochondrial apoptosis and experimental anti-cancer 
activity, provide initial validation for our strategy to 
identify compounds with 14-3-3-dimer disrupting activity 
as potential anti-cancer agents. 
In the present study we designed a series of new 
compounds that combine the quaternary ammonium 
group of the alkylated TMA molecules with the backbone 
of FTY720. The compounds exhibit varying ability to 
render 14-3-3 phosphorylatable in vitro coinciding with 
their ability to induce apoptosis of Jurkat cells (Figure 3). 
In particular RB-011 and RB-012 have a potent ability to 
induce apoptosis of Jurkat cells within 4 h of treatment 
and have ED50 values in the low micromolar range (Figure 
4). Time-course studies revealed rapid inactivation of 
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ERK and AKT signaling within 1 h of treatment of Jurkat 
cells with RB-012, followed by activation of SAPKs, 
JNK and p38 by 2 h (Figure 5A). The apoptotic cascade 
then proceeds with caspase-3 processing, PARP and BID 
cleavage (Figure 5B). These are important findings that 
reveal the cellular effects of RB-012 occur in a time-
dependent manner with primary effects on cell signaling 
occurring prior to apoptotic commitment. 
14-3-3 proteins are known to play a key role in 
integrating survival signaling within the cell [1-2]. 
When mutant forms of 14-3-3 that are non-competent 
for phospho-client binding are expressed in cells they 
heterodimerise with endogenous isoforms and act as 
functionally monomeric proteins, causing disruption of 
MAPK signaling and activation of SAPK [34, 35]. These 
effects phenocopy what we have observed with RB-012, 
and match the known differential regulation of upstream 
MAPK Raf-1 [36] and SAPKK, ASK-1 [37] and MEKK2 
[38] by dimeric 14-3-3 proteins. Additionally, recent 
studies have confirmed that 14-3-3 proteins are required 
for PI3K activity [39]. The downstream inactivation 
of AKT signaling in response to RB-012 is therefore 
entirely consistent with 14-3-3’s role in PI3K function. 
Our studies reveal that targeting 14-3-3 proteins using 
our sphingomimetic approach provides a potent means to 
disrupt functional 14-3-3 dimers which is desirable for an 
effective anti-cancer drug. 
Several isoforms of 14-3-3 have been associated 
with the transformed phenotype, both experimentally; 
over-expression of 14-3-3γ, β and ζ have been shown to 
cause cellular transformation [9, 40, 41], and in clinical 
samples (ζ, β, ε, γ, η and τ) [4-8]. However, the 14-3-3ζ 
isoform is the most commonly up-regulated in cancer 
[4-8]. This may be due to a specific role for the zeta 
isoform although to date none are known. More likely, 
the specific regulation of 14-3-3ζ expression by a micro-
RNA (miR-) 451 may be the underlying cause [42]. The 
negative regulation of 14-3-3ζ by miR-451 has been 
elegantly demonstrated in breast cancer cells where it 
was shown that tamoxifen treatment leads to loss of miR-
451 expression and up-regulation of 14-3-3ζ, correlating 
with increased disease severity [42]. Intriguingly, miR-
451 expression has also been shown to be low in NSCLC 
tissue compared with non-cancerous lung tissue, and up-
regulation of miR-451 in A549 cells reduced cell growth 
and increased the cells susceptibility to cisplatin [43]. 
These results mirror the over-expression 14-3-3ζ seen in 
NSCLC tissue which correlates with disease severity, and 
similarly targeted knock-down of 14-3-3ζ using RNAi in 
A549 cells also increased the cells sensitivity to cisplatin 
[4]. Thus the reciprocal expression of miR-451 and 14-
3-3ζ may be important prognostic markers for disease 
severity and cancer progression in NSCLC.
As 14-3-3ζ expression is closely linked with 
NSCLC disease, we tested RB-011 and RB-012 for anti-
cancer effects on NSCLC A549 cells. We found that 
these compounds inhibited A549 cell survival and colony 
formation in soft-agar and induced apoptosis (Figure 6). 
14-3-3ζ knock-down in A549 cells has previously been 
shown to reduce colony formation and increase anoikis 
(apoptosis induced by loss of cell adhesion) [11]. We also 
demonstrated the therapeutic potential of RB-012 in an 
in vivo A549-xenograft model (Figure 6) and showed 
that RB-012 reduces tumor growth by up to 30% over a 
three week course of treatment. The compound was well 
tolerated with fewer side effects than FTY720, which 
did not elicit a reduction in tumor growth. FTY720 has 
previously been demonstrated to reduce tumor growth 
in other experimental cancer models [21] but at higher 
doses (10 mg/kg/day), suggesting that the RB-012 is more 
potent. FTY720 is readily converted to a phospho-form 
by an endogenous sphingosine kinase (SK), and in this 
form acts as a sphingosine-1-phosphate analogue which 
mediates the drug’s immunosuppressive action. RB-012 
cannot be phosphorylated as it lacks a phosphate accepting 
hydroxyl group and unlike FTY720, does not affect SK 
activity [22]. Therefore compared to FTY720, RB-012 
has a more selective anti-cancer action. Compared with 
other 14-3-3-directed small molecules [13, 14 & 32], 
the RB compounds shown here are non-competitive 
in that they do not compete with endogenous phospho-
clients for binding in the amphipathic groove. These data 
provide valuable proof-of-principle for our 14-3-3 dimer 
disruption approach to cancer drug discovery. 
MATERIALS AND METHODS
Compounds
N-alkylated tri-methyl ammonium (TMA) 
compounds were purchased from Sigma. RB compounds 
were generated as mesylate salts and sodium mesylate was 
used in all relevant vehicle treatments.
RB-011, -012 and -015 were synthesized as 
described previously [22]. RB-066, RB-067, and RB-
068 were prepared by the following procedures and 
characterized by 1H and 13C NMR spectroscopy and 




To a solution of 4-octylphenethyl methanesulfonate 
(10 mg, 0.032 mmol) in 3 mL of acetonitrile was added 
N-methylmorpholine (70.4 µL, 0.64 mmol). The reaction 
mixture was stirred at 50°C for 2 d and concentrated. The 
residue was washed with hexane to give 7 mg (52%) of 
RB-066 as a yellow liquid; 1H NMR (400 MHz, CDCl3) 
δ 0.88 (t, J = 6.9 Hz, 3H), 1.26–1.29 (m, 10H), 1.57 (t, 
J = 7.9 Hz, 3H), 2.56 (t, J = 7.7 Hz, 3H), 2.76 (s, 3H), 
3.08–3.12 (m, 2H), 3.46 (s, 3H), 3.49–3.53 (m, 2H), 3.67–
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3.70 (m, 2H), 3.81–3.85 (m, 2H), 3.92–4.00 (m, 4H), 7.14 
(d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H); 13C NMR 
(100 MHz, CDCl3) δ 14.1, 22.7, 28.1, 29.3 (2C), 29.4, 
29.5, 31.5, 31.9, 35.6, 39.6, 42.8, 47.7, 60.7, 65.7, 128.9, 
129.3, 136.1, 142.0; ESI-HRMS (M + H)+ m/z calcd for 
C21H36NO 318.2797, found 318.2796.
1-Methyl-1-(4-octylphenethyl)-4-oxopiperidinium 
methanesulfonate (RB-067)
To a solution of 4-octylphenethyl methanesulfonate 
(10 mg, 0.032 mmol) in 3 mL of acetonitrile was added 
1-methyl-4-piperidone (74.7 µL, 0.64 mmol). The reaction 
mixture was stirred at 50°C for 2 d and concentrated. The 
residue was washed with hexane to give 8 mg (59%) of 
RB-067 as a yellow liquid; 1H NMR (400 MHz, CDCl3) 
δ 0.81 (t, J = 6.7 Hz, 3H), 1.02 (s, 9H), 1.12–1.25 (m, 
24H), 1.32–1.76 (m, 2H), 3.47–3.51 (m, 1H), 3.68–3.82 
(m, 3H), 4.20–4.23 (m, 1H), 4.47 (dd, J = 11.2, 19.6 Hz, 
2H), 7.16–7.20 (m, 4H), 7.26–7.40 (m, 6H), 7.57–7.62 (m, 
5H); 13C NMR (100 MHz, CDCl3) δ 14.1, 19.1, 22.7, 25.5, 
26.8, 26.8 (2C), 29.4 (2C), 29.5 (2C), 29.6, 29.7 (2C), 
31.9, 55.6, 63.9, 65.0, 72.1, 79.9, 127.7, 127.8 (3C), 127.9, 
128.4, 130.0, 135.6 (3C), 135.7, 137.9; ESI-HRMS (M + 
H)+ m/z calcd for C22H36NO 330.2797, found 330.2791.
8-Methyl-8-(4-octylphenethyl)-1,4-dioxa-8-
azoniaspiro[4.5]decane methanesulfonate (RB-068)
To a solution of 4-octylphenethyl methanesulfonate 
(10 mg, 0.032 mmol) in 3 mL of acetonitrile was added 
8-methyl-1,4-dioxa-8-azaspiro[4.5]decane (100 mg, 0.64 
mmol). The reaction mixture was stirred at 50°C for 24 
h and concentrated. The residue was washed with hexane 
to give 13 mg (85%) of RB-068 as a yellow liquid; 1H 
NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H), 1.26–
1.29 (m, 10H), 1.56 (t, J = 7.2 Hz, 2H), 1.90–1.94 (m, 
2H), 2.06–2.11 (m, 2H), 2.54 (t, J = 7.7 Hz, 2H), 2.73 (s, 
3H), 3.08–3.21 (m, 2H), 3.39(s, 3H), 3.57–3.61 (m, 2H), 
3.72–3.76(m, 4H), 3.94–4.00 (m, 4H), 7.12 (d, J = 8.0 
Hz, 2H), 7.23 (d, J = 8.0 Hz, 2H); 13C NMR (100 MHz, 
CDCl3) δ 14.1, 22.7, 27.0, 28.6, 29.3(2C), 29.5, 30.0, 
31.5, 31.6, 31.9, 35.5, 39.6, 59.8, 64.9, 65.0, 103.3, 128.9, 
129.2, 131.9, 142.5; ESI-HRMS (M + H)+ m/z calcd for 
C24H40NO2 374.3059, found 374.3055.
14-3-3 phosphorylation assays
Substrate 14-3-3 (0.5 μg of purified recombinant 14-
3-3) was added to 15 μl of reaction mixture comprising 
0.2U of the PKA catalytic subunit, in the presence or 
absence of compounds (delivered in 0.1% v/v ethanol) in 
PKA reaction buffer (10 mM Tris-HCl pH 7.4, 15 mM 
MgCl2, 3 mM DTT containing 25 μM ATP and 0.3 μCi 
[32P] γ-ATP). Reactions were incubated at 37°C for 15 min. 
After incubation, reactions were separated on 12.5% SDS-
PAGE and Coomassie stained. 14-3-3 phosphorylation was 
analyzed using a Typhoon Phosphorimager and quantified 
using Molecular Dynamics Image Q 5.2 software. 
PKA activity assays
Reactions were essentially identical to 14-3-3 
phosphorylation assays except that 50 µM kemptide 
substrate was added in place of 14-3-3 protein. After 
incubation at 37°C for 15 minutes the reactions were 
spotted onto phosphocellulose filters (Whatman P81). 
Filters were washed 5 times in 0.75% phosphoric acid and 
once in acetone before liquid scintillation counting.
Cell lines and culture
Jurkat E6.1 cells were obtained from the ATCC 
and verified by short tandem repeat (STR) analysis in 
December 2014. The A549 cell line was purchased 
from ECACC in April 2012 (which also performs STR 
verification) and used within 6 months of resuscitation 
in the studies presented here. Jurkat cells were routinely 
cultured in RPMI with 10% FBS and A549 cells in DMEM 
with 10% FBS at 37ºC with 5% CO2. Jurkat Bcl-2 cells 
were generated by lentiviral transduction using a third 
generation lentiviral construct as described previously 
[15] containing a Bcl-2α-IRES-IL2Rα encoding cassette. 
Transduced cells were FACS sorted for expression of 
IL2Rα using anti-CD25-PE (BD Pharmingen, #555433) 
(Supplementary Figure 1A) to enrich for Bcl-2 over-
expressing cells, and protein expression was further 
confirmed by immunoblotting with anti-Bcl-2 antibody 
(BD Transduction Laboratories, #610538) (Supplementary 
Figure 1B).
Apoptosis assays: TMRE, Caspase 3 and Annexin 
V
Jurkat cells were routinely set up in apoptosis assays 
at 2 x 105/ml in RPMI with 0.5% FBS. After treatment, 
cells were stained either with 200 nM TMRE, 5 µl/ml 
NucViewTM (Biotium), or Annexin V-FITC (Roche) for 
15 min prior to analysis by flow cytometry. Forward- and 
side-scatter properties were used to exclude debris and a 
‘viable’ gate corresponding to the intact PI negative cell 
population was used for fluorescence analysis. For A549, 
cells at 90% confluency were treated with the compounds 
for 48h in DMEM with 0.5% FBS. After treatment, 
cells were released with trypsin and then stained with 
NucViewTM prior to analysis by flow cytometry.
Assessment of A549 cell viability by MTS assay
A549 cells (2500/well) were plated in 96-well trays 
in DMEM with 0.5% FBS and cultured at 37ºC with 5% 
CO2 overnight. The following day RB compounds were 
Oncotarget14534www.impactjournals.com/oncotarget
added and the cells were incubated for a further 48 h 
prior to removal of the medium and replacement with 
MTS reagent (Promega) diluted 1:6 in Dulbecco’s PBS. 
The cells were incubated at 37ºC for a further 4 h and the 
conversion of MTS to the colored formazan compound 
was determined by measurement of absorbance at 490 nM. 
 A549 colony assay
A549 cells (7500) were plated in 0.33% low-melting 
point agarose in DMEM with 10 % FBS with and without 
RB compounds over a 0.5% low-melting point agarose 
base. Cells were incubated at 37ºC with 5% CO2 for 14 
days and then colonies were photographed and analyzed 
using Image J.
Immunoblotting
Jurkat cells were treated at 5 x 105/ml in RPMI 
with 0.5% FBS as detailed. Jurkat cells were harvested 
by centrifugation at 1500 g for 5 min and washed with 
PBS prior to lysis in homogenization buffer (20 mM 
Tris-HCl pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 5 % 
glycerol, protease inhibitor (Roche), 4 mM NaF, 2 mM 
sodium vanadate, 10 mM β-glycerophosphate, 1 mM 
sodium pyrophosphate, 1 mM sodium molybdate) for 
15 minutes on ice followed by three rounds of freeze-
thawing. For treatment A549 cells were plated in 10 cm 
dishes and treated when they reached approximately 75 % 
confluence in DMEM with 0.5% FBS. Cells were scraped 
from the dish and collected by centrifugation at 1500 g 
and washed with PBS prior to lysis in homogenization 
buffer as detailed above.
 All lysates were clarified at 13,000 rpm for 20 
minutes at 4°C and protein concentration was determined 
using the BCA assay (Pierce). Thirty to forty µg of lysate 
were run on Criterion-XT 4-12 % Bis-Tris gels (Bio-Rad), 
followed by transfer onto nitrocellulose. The filters were 
blocked for 30 min at room temperature in TNT buffer (10 
mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05 % Tween-20) 
containing blocking buffer (Roche), prior to incubation 
with antibodies over night. Antibodies used were from 
Cell Signaling Technology; phospho-p38 MAPK (#4571), 
phospho-SAPK/JNK (81E11), phospho- ERK (#9101), 
phospho-AKT S473 (#9271), ERK (#9102), AKT (#9272), 
BID (#2002), caspase-3 (#9602), PARP (#9542), and 
Santa Cruz Biotechnology; pan 14-3-3 K19 (sc-629) . 
After antibody binding, filters were washed in TNT for 1h 
at room temperature, incubated with 1/12,500 anti-rabbit 
or anti-mouse HRP secondary antibody (Pierce) for 1h at 
room temperature and finally washed for 1 hr with TNT 
before incubation with Clarity western ECL reagent (Bio-
Rad). Filters were exposed on a LAS 4000 imager. Blots 
were analyzed using Multi-gauge/Colony software FUJI 
FILM.
In vivo toxicity and xenograft studies
All experimental procedures involving animals were 
conducted in accordance with the NHMRC Australian 
Code for the Care and Use of Animals for Scientific 
Purposes and with approval by the institutional animal 
ethics committee. BALB/c nude mice (Nu/Nu, female, 5-6 
weeks old) were purchased from the Animal Resources 
Centre (Perth, WA) and maintained under pathogen-free 
conditions. 
Toxicity studies were carried out with both RB-012 
and FTY720 (in 0.9% saline) at 5 and 10 mg/kg body 
weight, administered daily by intraperitoneal injection and 
mice were monitored over a 28 day treatment course. Five 
mice were used per group for RB-012 treatment and three 
mice per group for FTY720 treatment.
For xenograft studies, A549 cells (5 x 106) in 100 µl 
of PBS were injected subcutaneously into the flanks of the 
mice and the resulting tumors were measured using digital 
calipers. The tumor volume was calculated using the 
following formula: Volume = (larger diameter) x (small 
diameter)2/2. Once the tumors had reached 100 mm3, 
mice were divided into groups of 9 and to each group 
was administered with either RB-012, FTY720 (in 0.9% 
saline) or saline by intraperitoneal injection daily. Initially, 
RB-012 and FTY720 were administered at 2 mg/kg body 
weight for two days and then the dose was increased to 5 
mg/kg body weight for two weeks, after which RB-012 
was increased to 10 mg/kg body weight but FTY720 was 
maintained at 5 mg/kg body weight. During this dosing 
regime tumors were monitored twice a week. Differences 
between samples were analyzed using 2-way ANOVA and 
statistical significance was accepted at P < 0.05.
Tissue preparation and analysis
At the end of the treatment courses, mice were 
euthanized and tissues were collected and fixed in 
neutral-buffered formalin for 12 hrs at 4°C. Tissues were 
processed by embedding in paraffin and cutting into 4 
µm sections. Sections were dewaxed and rehydrated 
and the antigen retrieved by boiling for 20 minutes in 
10 mM citrate buffer (pH 6.0) under pressure (65 kPa 
above atmospheric pressure). Sections were blocked 
with 10 % goat serum in PBS (pH 7.4) solution for 30 
minutes and incubated with rabbit anti-phospho-ERK 
(1:100 diluted; CST #9101) at 4°C overnight. Sections 
were washed three times in PBS containing 0.1 % 
Tween and incubated with anti-rabbit IgG conjugated 
to Alexa Fluor-488 (1:400 diluted; Invitrogen) at room 
temperature for one hour. Sections were washed as before 
and mounted in vectashield hard-set mounting medium 
(Vector) containing DAPI and imaged using a LSM 710 
two-photon microscope (Zeiss). Images were analyzed 
using ImageJ software (NIH) to calculate percentage area 
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coverage by fluorescence signal per image using a binary 
converted image based on a single manually determined 
threshold value applied across all images (as previously 
described) [23,24]. Results are expressed as medians with 
ranges and quartiles across all data sets.
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